FDA warned Pink Pony Peptides that its GLP-2 TZ, GLP-3 RT and Bacteriostatic Water are unapproved new drugs sold online.
What happened
In December 2025, FDA reviewed pinkponypeptides.com and found it offered GLP-2 TZ, GLP-3 RT, and Bacteriostatic Water for sale in the United States. FDA says the products are unapproved new drugs and that website labeling—despite “laboratory research purposes only” and “not for human consumption” statements—shows they are intended for human use as drugs. FDA also says injectable products pose risks of serious harm because they bypass some body defenses.
What FDA found
FDA says Pink Pony Peptides offered GLP-2 TZ, GLP-3 RT, and Bacteriostatic Water for sale in the United States without FDA-approved applications.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)FDA says website labeling for the products—including claims about appetite, blood sugar, fat loss, and metabolic function—shows they are intended to treat disease or affect body structure or function.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128FDA says the products are “new drugs” because they are not generally recognized as safe and effective for the uses described in their labeling.
FD&C Act section 201(p), 21 U.S.C. 321(p)FDA says selling Bacteriostatic Water alongside injectable peptide products shows it is intended for use in injection and is therefore a drug.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receiving the letter about specific steps taken to correct the violations, with an explanation and related documentation. If the company believes the products are not in violation, FDA asks for its reasoning and supporting information.
Who should pay attention
- online sellers of research-labeled peptides
- clinics or med spas buying injectable peptides
- consumers considering injectable GLP products
This is a summary. Read the original letter on fda.gov.